[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499287":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":107,"collaborators":26,"id":109,"slug":26,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":110,"sex":116,"minAge":26,"maxAge":117,"enrollmentInfo":118,"targetDuration":26,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Institut Curie","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TauroLock™","EXPERIMENTAL","The patient will be followed up to a maximum of 6 months after randomization after have a Taurlock™ injected each time catheter will be used.",[13],"Device: TaurolockTM",{"label":15,"type":16,"description":17,"interventionNames":18},"Physiological serum (NaCl 0.9%)","PLACEBO_COMPARATOR","The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.",[19],"Device: Physiological serum",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","TaurolockTM","The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.",[9],null,{"type":22,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Physiological serum",[15],[31],{"name":32,"affiliation":5,"role":33},"Camille CORDERO, MD","STUDY_DIRECTOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","+33172389309","camille.cordero@curie.fr",{"name":40,"role":36,"phone":26,"phoneExt":26,"email":41},"Marie-Emmanuelle Legrier, PhD","drci.promotion@curie.fr",[43,60,71,82,93],{"facility":5,"status":44,"city":45,"state":26,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Paris","75005","France",{"type":49,"coordinates":50},"Point",[51,52],2.3488,48.85341,{"lat":52,"lon":51},[55,58],{"name":56,"role":36,"phone":26,"phoneExt":26,"email":57},"Lauriane LEMELLE, MD","lauriane.lemelle@curie.fr",{"name":56,"role":59,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"facility":61,"status":44,"city":45,"state":26,"zip":62,"country":47,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Saint Louis","75010",{"type":49,"coordinates":64},[51,52],{"lat":52,"lon":51},[67,70],{"name":68,"role":36,"phone":26,"phoneExt":26,"email":69},"Florence RABIAN, MD","florence.rabian@aphp.fr",{"name":68,"role":59,"phone":26,"phoneExt":26,"email":26},{"facility":72,"status":44,"city":45,"state":26,"zip":73,"country":47,"cosmosGeoPoint":74,"geoPoint":76,"contacts":77},"Armand Trousseau","75012",{"type":49,"coordinates":75},[51,52],{"lat":52,"lon":51},[78,81],{"name":79,"role":36,"phone":26,"phoneExt":26,"email":80},"Arnaud PETIT, MD","arnaud.petit@aphp.fr",{"name":79,"role":59,"phone":26,"phoneExt":26,"email":26},{"facility":83,"status":44,"city":45,"state":26,"zip":84,"country":47,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"Robert Debre","75935",{"type":49,"coordinates":86},[51,52],{"lat":52,"lon":51},[89,92],{"name":90,"role":36,"phone":26,"phoneExt":26,"email":91},"Benoit BRETHON, MD","benoit.brethon@aphp.fr",{"name":90,"role":59,"phone":26,"phoneExt":26,"email":26},{"facility":94,"status":44,"city":95,"state":26,"zip":96,"country":47,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Gustave Roussy","Villejuif","94805",{"type":49,"coordinates":98},[99,100],2.35992,48.7939,{"lat":100,"lon":99},[103,106],{"name":104,"role":36,"phone":26,"phoneExt":26,"email":105},"Charlotte RIGAUD, MD","charlotte.rigaud@gustaveroussy.fr",{"name":104,"role":59,"phone":26,"phoneExt":26,"email":26},{"type":108,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100499287",false,"NCT05781295","Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology","Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in the Primary Prevention of Catheter-related Endoluminal Infection in Paediatric Oncology.","PEDIALOCK","Inclusion Criteria:\n\n1. Patient less than or equal to 21 years of age at inclusion.\n2. Patient for whom a central catheter is planned to be inserted\\*, excluding a non-tunneled femoral or cervical external catheter or a peripherally inserted central catheter (as PICC line). \\*1st catheter placement or placement following a relapse (this placement must take place at least one month after previous catheter removal).\n3. Patient treated for a cancer.\n4. Patient with regular follow-up in the inclusion center.\n5. Informed consent signed by the patient if adult or by legal representatives if minor.\n6. Patient benefiting from a social security coverage.\n7. Time between the date of catheter placement and the planned date for the first solution lock injection less than 6 weeks.\n\nExclusion Criteria:\n\n1. Patient with retinoblastoma.\n2. Allografted patient.\n3. Patient with a life expectancy of less than 6 months.\n4. Patient refusing to participate in the protocol.\n5. Patient already receiving a central venous catheter-related infection prevention lock (ILCVC).\n6. Patient with known allergy to citrate or (cyclo)-Taurolidine.\n7. Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine.\n8. Patient with an external femoral catheter.\n9. Patient with a PICCLINE-type peripheral venous inserted central catheter.\n10. Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.\n11. Patient under guardianship and curatorship.","ALL","21 Years",{"count":119,"type":120},148,"ESTIMATED","INTERVENTIONAL",[123],"NA","Interest of a Taurolidine lock at each catheter closure in the primary prevention of catheter-related endoluminal infection in paediatric oncology.\n\nMulticentric, controlled, randomized and double-blind label study.",[126,127,128,129],"Children","Medical Device","Primary Prevention","Oncology","2026-02-18",{"date":132,"type":133},"2026-02-20","ACTUAL",{"date":135,"type":133},"2024-01-19",{"date":137,"type":120},"2028-07-23",{"name":5,"class":6},5]